Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

ClinicalTrials.gov ID: NCT04187144

Public ClinicalTrials.gov record NCT04187144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

Study identification

NCT ID
NCT04187144
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,606 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 23, 2020 (Actual)
Primary completion
Dec 1, 2022 (Actual)
Completion
Dec 1, 2022 (Actual)
Last update posted
Jul 18, 2023

2020 – 2022

United States locations

U.S. sites
79
U.S. states
22
U.S. cities
69
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205 —
GSK Investigational Site Homewood Alabama 35209 —
GSK Investigational Site Huntsville Alabama 35801 —
GSK Investigational Site Gilbert Arizona 85296 —
GSK Investigational Site Peoria Arizona 85381-3689 —
GSK Investigational Site Phoenix Arizona 85015-1104 —
GSK Investigational Site La Mesa California 91942 —
GSK Investigational Site Modesto California 95350-5365 —
GSK Investigational Site Northridge California 91324 —
GSK Investigational Site Sacramento California 95821 —
GSK Investigational Site Valencia California 91355-5319 —
GSK Investigational Site Washington D.C. District of Columbia 20011 —
GSK Investigational Site Apollo Beach Florida 33572 —
GSK Investigational Site Boynton Beach Florida 33435 —
GSK Investigational Site Clearwater Florida 33761 —
GSK Investigational Site Coconut Creek Florida 33063 —
GSK Investigational Site Gainesville Florida 32607 —
GSK Investigational Site Hialeah Florida 33013 —
GSK Investigational Site Lake Worth Florida 33461 —
GSK Investigational Site Leesburg Florida 34748 —
GSK Investigational Site Miami Florida 33126 —
GSK Investigational Site Miami Florida 33135 —
GSK Investigational Site Miami Florida 33155 —
GSK Investigational Site Miami Florida 33186-2178 —
GSK Investigational Site Orlando Florida 32810 —
GSK Investigational Site Ormond Beach Florida 32174 —
GSK Investigational Site Palm Springs Florida 33406 —
GSK Investigational Site Pembroke Pines Florida 33026-4383 —
GSK Investigational Site Plant City Florida 33563 —
GSK Investigational Site Sweetwater Florida 33172 —
GSK Investigational Site Tampa Florida 33614 —
GSK Investigational Site West Palm Beach Florida 33409 —
GSK Investigational Site Blackfoot Idaho 83221 —
GSK Investigational Site Boise Idaho 83704 —
GSK Investigational Site Meridian Idaho 83642 —
GSK Investigational Site Hanover Maryland 21076 —
GSK Investigational Site Fall River Massachusetts 02723 —
GSK Investigational Site Butte Montana 59701 —
GSK Investigational Site Lincoln Nebraska 68510 —
GSK Investigational Site East Orange New Jersey 07018-1502 —
GSK Investigational Site Lawrenceville New Jersey 08648 —
GSK Investigational Site Mount Laurel New Jersey 08054 —
GSK Investigational Site Brooklyn New York 11229 —
GSK Investigational Site New York New York 10016-7313 —
GSK Investigational Site New York New York 10016 —
GSK Investigational Site The Bronx New York 10456 —
GSK Investigational Site Cary North Carolina 27518 —
GSK Investigational Site Wilmington North Carolina 28412 —
GSK Investigational Site Winston-Salem North Carolina 27103 —
GSK Investigational Site Fargo North Dakota 58104 —
GSK Investigational Site Cincinnati Ohio 45215 —
GSK Investigational Site Columbus Ohio 43213 —
GSK Investigational Site Columbus Ohio 43214 —
GSK Investigational Site Columbus Ohio 43231 —
GSK Investigational Site Dayton Ohio 45424 —
GSK Investigational Site Eugene Oregon 97404 —
GSK Investigational Site Bala-Cynwyd Pennsylvania 19004 —
GSK Investigational Site Philadelphia Pennsylvania 19107 —
GSK Investigational Site Greenville South Carolina 29615 —
GSK Investigational Site Lancaster South Carolina 29720 —
GSK Investigational Site Union South Carolina 29379 —
GSK Investigational Site Milan Tennessee 38358 —
GSK Investigational Site New Tazewell Tennessee 37824-1409 —
GSK Investigational Site Austin Texas 78735 —
GSK Investigational Site Austin Texas 78744 -1645 —
GSK Investigational Site Houston Texas 77087 —
GSK Investigational Site Katy Texas 77450 —
GSK Investigational Site Mesquite Texas 75149 —
GSK Investigational Site Missouri City Texas 77459 —
GSK Investigational Site North Richland Hills Texas 76180 —
GSK Investigational Site Plano Texas 75024 —
GSK Investigational Site San Antonio Texas 78209 —
GSK Investigational Site San Antonio Texas 78229 —
GSK Investigational Site San Antonio Texas 78251 —
GSK Investigational Site Bountiful Utah 84010 —
GSK Investigational Site Salt Lake City Utah 84107 —
GSK Investigational Site St. George Utah 84790 —
GSK Investigational Site Richmond Virginia 23225 —
GSK Investigational Site Richmond Virginia 23235 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04187144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2023 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04187144 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →